TY - JOUR
T1 - Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
AU - Sobas, Marta Anna
AU - Turki, Amin T
AU - Ramiro, Angela Villaverde
AU - Hernández-Sánchez, Alberto
AU - Elicegui, Javier Martinez
AU - González, Teresa
AU - Melchor, Raúl Azibeiro
AU - Abáigar, María
AU - Tur, Laura
AU - Dall'Olio, Daniele
AU - Sträng, Eric
AU - Tettero, Jesse M
AU - Castellani, Gastone
AU - Benner, Axel
AU - Döhner, Konstanze
AU - Thiede, Christian
AU - Metzeler, Klaus H
AU - Haferlach, Torsten
AU - Damm, Frederik
AU - Ayala, Rosa
AU - Martínez-López, Joaquín
AU - Mills, Ken I
AU - Sierra, Jorge
AU - Lehmann, Sören
AU - Porta, Matteo G Della
AU - Mayer, Jiri
AU - Reinhardt, Dirk
AU - Medina, Rubén Villoria
AU - Schulze-Rath, Renate
AU - Barbus, Martje
AU - Hernández-Rivas, Jesús María
AU - Huntly, Brian J P
AU - Ossenkoppele, Gert
AU - Döhner, Hartmut
AU - Bullinger, Lars
PY - 2024/11/7
Y1 - 2024/11/7
N2 - Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.
AB - Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5- year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate has dropped from 13.0% to 4.7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients.
KW - acute myeloid leukemia
KW - leukemia
KW - HARMONY Alliance
KW - intensive treatment
U2 - 10.3324/haematol.2024.285805
DO - 10.3324/haematol.2024.285805
M3 - Article
C2 - 39506894
SN - 0390-6078
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
ER -